Literature DB >> 9093631

Comparative efficacy of halofantrine, chloroquine and sulfadoxine-pyrimethamine for treatment of acute uncomplicated falciparum malaria in Nigerian children.

C O Falade1, L A Salako, A Sowunmi, A M Oduola, P Larcier.   

Abstract

One hundred and ten children aged 6 months to 11 years were randomly treated with halofantrine (HF), sulfadoxine-pyrimethamine (S-P) or chloroquine (CQ) for acute uncomplicated Plasmodium falciparum malaria in an endemic area of south-western Nigeria. The response of infection to treatment in each child was monitored for 14 d. The mean fever clearance times were 1.9 d (n = 36), 1.6 d (n = 27), and 1-7 d (n = 28) for children treated with HF, S-P and CQ, respectively. The parasite clearance times were 3.4 d (n = 39), 4.4 d (n = 24) and 4.1 d (n = 15) in the 3 groups of children. The cure rate at day 7 was 92.3% (36/39) in children treated with HF, 72.7% (24/33) in those treated with S-P, and 39.5% (15/38) in those treated with CQ. By day 14, 4 of 36 (11.1%) parasitologically cured patients treated with HF had experienced recrudescences. The corresponding figures among children treated with S-P or CQ were 8.3% and 13.3%, respectively. The 3 drugs were well tolerated. The results of the study showed a further decline in the sensitivity of P. falciparum infections to CQ, while HF and S-P remained relatively effective in the treatment of malaria in south-west Nigeria.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093631     DOI: 10.1016/s0035-9203(97)90397-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

Review 1.  History, dynamics, and public health importance of malaria parasite resistance.

Authors:  Ambrose O Talisuna; Peter Bloland; Umberto D'Alessandro
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

2.  Molecular surveillance of drug-resistant Plasmodium falciparum in two distinct geographical areas of Nigeria.

Authors:  Olusola Ojurongbe; Segun I Oyedeji; Wellington A Oyibo; Adetola F Fagbenro-Beyioku; Jürgen F Kun
Journal:  Wien Klin Wochenschr       Date:  2010-11-12       Impact factor: 1.704

3.  Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine.

Authors:  Jens Graupner; Klaus Göbels; Martin P Grobusch; Anne Lund; Joachim Richter; Dieter Häussinger
Journal:  Parasitol Res       Date:  2005-04-28       Impact factor: 2.289

4.  Concentrations of chloroquine and malaria parasites in blood in Nigerian children.

Authors:  F P Mockenhaupt; J May; Y Bergqvist; O G Ademowo; P E Olumese; A G Falusi; L Grossterlinden; C G Meyer; U Bienzle
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

5.  Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial.

Authors:  Martin Meremikwu; Ambrose Alaribe; Regina Ejemot; Angela Oyo-Ita; John Ekenjoku; Chukwuemeka Nwachukwu; Donald Ordu; Emmanuel Ezedinachi
Journal:  Malar J       Date:  2006-05-16       Impact factor: 2.979

6.  Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapy.

Authors:  Grace O Gbotosho; Christian T Happi; Abideen Ganiyu; Olumide A Ogundahunsi; Akin Sowunmi; Ayoade M Oduola
Journal:  Malar J       Date:  2009-12-30       Impact factor: 2.979

7.  An in-depth study of patent medicine sellers' perspectives on malaria in a rural Nigerian community.

Authors:  Theodora A Okeke; Benjamin S C Uzochukwu; Henrietta U Okafor
Journal:  Malar J       Date:  2006-11-01       Impact factor: 2.979

8.  A qualitative study of the feasibility and community perception on the effectiveness of artemether-lumefantrine use in the context of home management of malaria in south-west Nigeria.

Authors:  Ikeoluwapo O Ajayi; Catherine O Falade; Benjamin O Olley; Bidemi Yusuf; Sola Gbotosho; Toyin Iyiola; Omobola Olaniyan; Christian Happi; Kaendi Munguti; Franco Pagnoni
Journal:  BMC Health Serv Res       Date:  2008-06-01       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.